NZ526914A - Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases - Google Patents

Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases

Info

Publication number
NZ526914A
NZ526914A NZ526914A NZ52691402A NZ526914A NZ 526914 A NZ526914 A NZ 526914A NZ 526914 A NZ526914 A NZ 526914A NZ 52691402 A NZ52691402 A NZ 52691402A NZ 526914 A NZ526914 A NZ 526914A
Authority
NZ
New Zealand
Prior art keywords
alkyl
compound
oxo
dimethyl
tetrahydrofuran
Prior art date
Application number
NZ526914A
Other languages
English (en)
Inventor
Martin Quibell
Original Assignee
Amura Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0101187.3A external-priority patent/GB0101187D0/en
Application filed by Amura Therapeutics Ltd filed Critical Amura Therapeutics Ltd
Publication of NZ526914A publication Critical patent/NZ526914A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ526914A 2001-01-17 2002-01-17 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases NZ526914A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0101187.3A GB0101187D0 (en) 2001-01-17 2001-01-17 Biologically active compounds
US27550501P 2001-03-13 2001-03-13
PCT/GB2002/000190 WO2002057249A1 (fr) 2001-01-17 2002-01-17 2-carbonylaminocetones cycliques, inhibiteurs de la cruzipain et autres cysteine proteases

Publications (1)

Publication Number Publication Date
NZ526914A true NZ526914A (en) 2005-02-25

Family

ID=26245572

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ526914A NZ526914A (en) 2001-01-17 2002-01-17 Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases

Country Status (6)

Country Link
EP (1) EP1362042A1 (fr)
JP (1) JP2004522738A (fr)
CA (1) CA2435117A1 (fr)
IL (1) IL156775A0 (fr)
NZ (1) NZ526914A (fr)
WO (1) WO2002057249A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7030116B2 (en) 2000-12-22 2006-04-18 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
US7064123B1 (en) 2000-12-22 2006-06-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin inhibitors
IL160819A0 (en) 2001-09-14 2004-08-31 Aventis Pharma Inc Novel compounds and compositions as cathepsin inhibitors
CN1324018C (zh) 2001-11-14 2007-07-04 安万特药物公司 作为组织蛋白酶s抑制剂的寡肽以及含有它们的组合物
WO2006064286A1 (fr) * 2004-12-13 2006-06-22 Medivir Uk Ltd Inhibiteurs de cathepsine s
US9409880B2 (en) 2011-01-20 2016-08-09 The Regents Of The University Of Colorado, A Body Corporate Modulators of TLR3/dsRNA complex and uses thereof
IN2015MN00405A (fr) * 2012-08-30 2015-09-04 Univ Tokyo

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008802A1 (fr) * 1996-08-28 1998-03-05 Smithkline Beecham Corporation Inhibiteurs de cysteine protease
EA002100B1 (ru) * 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
AR013079A1 (es) * 1997-05-06 2000-12-13 Smithkline Beecham Corp Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
CO5150165A1 (es) * 1998-11-13 2002-04-29 Smithkline Beecham Plc Inhibidores de proteasa: tipo catepsina k
GB9911417D0 (en) * 1999-05-18 1999-07-14 Peptide Therapeutics Ltd Furanone derivatives as inhibitors of cathepsin s

Also Published As

Publication number Publication date
CA2435117A1 (fr) 2002-07-25
WO2002057249A1 (fr) 2002-07-25
EP1362042A1 (fr) 2003-11-19
JP2004522738A (ja) 2004-07-29
IL156775A0 (en) 2004-02-08

Similar Documents

Publication Publication Date Title
AU2002219397B2 (en) Inhibitors of cruzipain and other cysteine proteases
AU2002219397A1 (en) Inhibitors of cruzipain and other cysteine proteases
EP1546150B1 (fr) Derives de pyrrole en tant qu'inhibiteurs de cysteine protease
NZ526914A (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
NZ526912A (en) Inhibitors of cruzipain and other cysteine proteases
US7132449B2 (en) Inhibitors of cruzipain and other cysteine proteases
AU2006277710A1 (en) Preparation of diazapentalene derivatives via epoxydation of dihydropyrroles
US20040127549A1 (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
AU2002219399A1 (en) Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
WO2007023281A2 (fr) Composes biologiquement actifs
AU2002225157A1 (en) Inhibitors of cruzipain and other cysteine proteases
BRPI0206501B1 (pt) An inhibitor compound of cruzipain and other cysteine ​​proteases, their uses, their pharmaceutical or veterinary composition, the process for the preparation of said composition and the method of establishing whether a cysteine ​​protease contributes to a biochemical function
KR100632800B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 신규한하이드록시아마이드 유도체 및 이의 제조 방법
KR20050019877A (ko) 생물학적으로 활성이 있는 화합물
EP0934944A1 (fr) Dérivés de 7-bromo- et 7,7-dibromo céphéme et céphame et leur utilisation comme inhibiteurs de protéases

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)